# SYNAGEVA BIOPHARMA CORP

SYNAGEVA BIOPHARMA CORP is a company headquartered in Lexington, MA, United States.

## Company overview

- **Legal name:** SYNAGEVA BIOPHARMA CORP
- **Former names in filing history:** TRIMERIS INC (1997-10-01 to 2011-10-13)
- **Classification:** Company
- **Industry (SIC):** 2836 — Biological Products, (No Diagnostic Substances)
- **Headquarters:** Lexington, MA, United States
- **Incorporated in:** DE
- **Fiscal year end:** December 31
- **SEC CIK:** 0000911326

## About

SYNAGEVA BIOPHARMA CORP is identified in the retained SEC EDGAR snapshot dated 2026-10-14. Its SEC Central Index Key is 0000911326, and its reported industry is Biological Products, (No Diagnostic Substances). In 10-K filed on 2015-02-26, it reported annual revenue of USD 6,492,000; net income of USD -192,648,000; total assets of USD 504,203,000 for the fiscal period ended 2014-12-31. The financial history preserves reporting periods, currencies, filing accessions and source provenance. Figures are reported filing data, rather than real-time estimates.

## Financials

Annual figures as originally reported. Currency is shown for each fiscal year; B means billion and M means million.

### FY2014 (period ended 2014-12-31)

- **Revenue:** $6.5M (USD 6,492,000)
- **Net income:** -$192.6M (USD -192,648,000)
- **Total assets:** $504.2M (USD 504,203,000)
- **Cash and equivalents:** $82.7M (USD 82,653,000)

### FY2013 (period ended 2013-12-31)

- **Revenue:** $13.4M (USD 13,374,000)
- **Net income:** -$95.5M (USD -95,450,000)
- **Total assets:** $447.9M (USD 447,949,000)
- **Cash and equivalents:** $62.1M (USD 62,137,000)
- **Operating cash flow:** -$75.0M (USD -75,002,000)

### FY2012 (period ended 2012-12-31)

- **Revenue:** $15.0M (USD 14,954,000)
- **Net income:** -$42.9M (USD -42,949,000)
- **Total assets:** $243.3M (USD 243,256,000)
- **Cash and equivalents:** $23.9M (USD 23,883,000)
- **Operating cash flow:** -$30.9M (USD -30,935,000)

### FY2011 (period ended 2011-12-31)

- **Revenue:** $2.1M (USD 2,098,780)
- **Net income:** -$25.3M (USD -25,305,882)
- **Total assets:** $83.3M (USD 83,298,068)
- **Cash and equivalents:** $60.2M (USD 60,231,712)
- **Operating cash flow:** -$16.6M (USD -16,589,431)
- **Later filings:** Revenue, Net income, Total assets, Cash and equivalents, Operating cash flow: shown as originally filed; later filings report different values for the same periods.

## Recent SEC filings

- Form 8-K — filed 2015-06-23 — period 2015-06-19 — FORM 8-K
- Form 8-K — filed 2015-05-06 — period 2015-05-05 — FORM 8-K
- Form 10-Q — filed 2015-04-30 — period 2015-03-31 — FORM 10-Q
- Form 8-K — filed 2015-04-29 — period 2015-04-29 — 8-K
- Form DEF 14A — filed 2015-04-28 — period 2015-06-26 — NOTICE & PROXY STATEMENT
- Form 10-K — filed 2015-02-26 — period 2014-12-31 — FORM 10-K
- Form 8-K — filed 2015-02-26 — period 2015-02-26 — FORM 8-K
- Form 8-K — filed 2015-02-09 — period 2015-02-04 — FORM 8-K
- Form 8-K — filed 2015-02-02 — period 2015-01-28 — FORM 8-K
- Form 8-K — filed 2015-01-07 — period 2015-01-05 — 8-K
- Form 10-Q — filed 2014-10-30 — period 2014-09-30 — 10-Q
- Form 8-K — filed 2014-10-30 — period 2014-10-30 — 8-K

---

Updated: 2026-10-23T20:10:52Z

Canonical page: https://altss.com/profile/synageva-biopharma-corp

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology